Biogen (NASDAQ:BIIB) Upgraded by UBS Group to Buy Rating

UBS Group upgraded shares of Biogen (NASDAQ:BIIB) from a neutral rating to a buy rating in a research report sent to investors on Wednesday, MarketBeat.com reports. The firm currently has $225.00 price target on the biotechnology company’s stock, up from their previous price target of $185.00.

Several other research firms have also commented on BIIB. Citigroup decreased their price target on shares of Biogen from $215.00 to $190.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Royal Bank Of Canada reduced their price objective on shares of Biogen from $233.00 to $213.00 and set an “outperform” rating for the company in a research note on Tuesday, April 7th. HSBC increased their target price on shares of Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a research report on Tuesday, March 17th. BMO Capital Markets lifted their price target on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday, February 6th. Finally, Barclays assumed coverage on Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price target on the stock. Fourteen analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Biogen has a consensus rating of “Hold” and a consensus target price of $209.77.

Biogen Trading Up 2.2%

Shares of NASDAQ:BIIB opened at $190.07 on Wednesday. The company has a market capitalization of $27.89 billion, a PE ratio of 21.57, a P/E/G ratio of 2.48 and a beta of 0.16. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen has a 12-month low of $115.25 and a 12-month high of $202.41. The business’s fifty day simple moving average is $185.53 and its 200-day simple moving average is $174.73.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the business posted $3.44 EPS. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts predict that Biogen will post 15.82 earnings per share for the current fiscal year.

Insider Activity

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Hedge funds have recently made changes to their positions in the company. Reflection Asset Management purchased a new position in Biogen in the 4th quarter worth $25,000. WPG Advisers LLC grew its stake in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the last quarter. Accredited Wealth Management LLC grew its stake in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the last quarter. First Horizon Corp acquired a new position in shares of Biogen in the fourth quarter valued at about $30,000. Finally, WFA of San Diego LLC acquired a new position in shares of Biogen in the second quarter valued at about $32,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy from Neutral and raised its price target to $225, citing a “slew of pipeline catalysts” across the next 12–15 months (readouts and commercialization milestones that could meaningfully re‑rate the stock). Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Positive Sentiment: Biogen secured Greater China rights to felzartamab (the immune‑disease antibody) — the deal gives Biogen another late‑stage asset as global phase IIIs progress and supports commercial optionality in a large market. BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
• Positive Sentiment: Biogen announced a strategic deal with TJ Biopharma (transaction details reported to expand Biogen’s pipeline/partnership footprint), which traders viewed as supportive of near‑term momentum. Biogen Zooms on Deal with TJ Biopharma
• Neutral Sentiment: Analyst commentary and aggregator coverage (TipRanks/press summaries) amplify the UBS thesis (mentions of Apellis acquisition and valuation discount), reinforcing the bullish narrative but largely repeating the same catalysts. Biogen: Underappreciated Late‑Stage Pipeline, Apellis Acquisition…
• Negative Sentiment: HSBC maintains a Reduce rating and a $150 target, publishing conservative multi‑year EPS forecasts — a counterpoint to UBS that highlights downside risk if pipeline readouts or commercial execution disappoint. MarketBeat Biogen coverage (HSBC estimates)
• Negative Sentiment: A Zacks earnings preview warns Q1 revenue/earnings may decline vs. year‑ago levels, reminding investors of near‑term volatility and execution risk ahead of upcoming results. Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.